Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma

被引:18
作者
Kleinstern, Geffen [1 ,2 ]
Averbuch, Mor [1 ]
Abu Seir, Rania [3 ,4 ]
Perlman, Riki [3 ]
Ben Yehuda, Dina [3 ]
Paltiel, Ora [1 ,3 ]
机构
[1] Hadassah Hebrew Univ, Med Ctr, Sch Publ Hlth, Jerusalem, Israel
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[3] Hadassah Hebrew Univ, Med Ctr, Dept Hematol, Jerusalem, Israel
[4] Al Quds Univ, Dept Med Lab Sci, Jerusalem, Israel
基金
以色列科学基金会;
关键词
autoimmune disease; diffuse large B-cell lymphoma; non-Hodgkin lymphoma; risk; survival; RHEUMATOID-ARTHRITIS;
D O I
10.1002/hon.2498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although autoimmune diseases (AIDs) are known to predispose to non-Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B-cell NHL onset by comparing AID history (determined by self-report and medication review and supplemented by chart review where possible) among 435 adult B-NHL patients in Hadassah-Hebrew University Medical Center, diagnosed 2009-2014, and 414 age-and-sex frequency-matched controls. We examined AIDs as a whole, B- and T-cell-mediated AIDs, and autoimmune thyroid diseases. Among cases, we used Kaplan-Meier and Cox regression models to assess the association of AID with overall survival and relapse-free survival, adjusting for prognostically important patient and disease characteristics such as Ki67% staining, International Prognostic Index, rituximab treatment, and histological subgroup. Autoimmune diseases were associated with B-NHL (odds ratio [OR] = 1.95; 95% confidence interval (CI), 1.31-2.92), especially AIDs mediated by B-cell activation (OR = 5.20; CI, 1.90-14.3), which were particularly associated with marginal zone lymphoma (OR = 19.3; CI, 4.59-80.9). We found that time to relapse for all B-NHL patients with AIDs was significantly shorter (mean of 49.21mo [+/- 3.22]) than among patients without AID (mean of 59.74mo [+/- 1.62]), adjusted hazard ratio [HRadj] = 1.69 (CI, 1.03-2.79). Specifically, in patients with diffuse large B-cell lymphoma, of whom 91.8% had received rituximab, a history of B-cell-mediated AIDs was associated with shorter relapse-free survival and overall survival, HRadj = 8.34 (CI, 3.01-23.1) and HRadj = 3.83 (CI, 1.20-12.3), respectively. Beyond confirming the well-known association between AIDs and B-NHL, we found that AID is an adverse prognostic factor in B-cell lymphoma, associated with a shortened time to relapse, suggesting that there are specific therapeutic challenges in the subgroup of patients suffering from both these diseases. Further work is required to address mechanisms of resistance to standard treatment in the setting of AID-associated B-NHL. In the era of immunotherapy, these findings have particular relevance.
引用
收藏
页码:457 / 462
页数:6
相关论文
共 50 条
[41]   The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma [J].
Gaman, Amelia ;
Bold, Adriana ;
Gaman, G. .
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2011, 52 (02) :719-722
[42]   A case of pericardial schistosomiasis and non-Hodgkin high grade B-cell lymphoma [J].
Boyd, Michael J. ;
Mendelson, Marc ;
Dlamini, Sipho K. ;
Wasserman, Sean ;
Fakier, Ghaalied ;
Roberts, Riyaadh ;
Papavarnavas, Nectarios S. .
SOUTHERN AFRICAN JOURNAL OF INFECTIOUS DISEASES, 2023, 38 (01)
[43]   Rhinopharyngeal B-cell non-hodgkin lymphoma - Unusual presentation with massive hematemesis [J].
Manzitti, Carla ;
Barabino, Arrigo ;
Bosio, Victoria ;
Gambini, Claudio ;
Battaglia, Teresa ;
Garaventa, Alberto .
PEDIATRIC EMERGENCY CARE, 2007, 23 (04) :231-233
[44]   Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children [J].
Giulino-Roth, Lisa ;
Goldman, Stanton .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (04) :531-544
[45]   Aberrant Expression of CD8 in B-Cell Non-Hodgkin Lymphoma [J].
Carulli, Giovanni ;
Stacchini, Alessandra ;
Marini, Alessandra ;
Ciriello, Maria Matilde ;
Zucca, Alessandra ;
Cannizzo, Elisa ;
Aliberti, Sabrina ;
Demurtas, Anna ;
Novero, Domenico ;
Calcagno, Lara ;
Callegari, Tiziana ;
Petrini, Mario .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (02) :186-190
[46]   Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma [J].
Spasevska, Ivana ;
Sharma, Ankush ;
Steen, Chloe B. ;
Josefsson, Sarah E. ;
Blaker, Yngvild N. ;
Kolstad, Arne ;
Rustad, Even H. ;
Meyer, Saskia ;
Isaksen, Kathrine ;
Chellappa, Stalin ;
Kushekhar, Kushi ;
Beiske, Klaus ;
Forsund, Mette S. ;
Spetalen, Signe ;
Holte, Harald ;
Ostenstad, Bjorn ;
Brodtkorb, Marianne ;
Kimby, Eva ;
Olweus, Johanna ;
Tasken, Kjetil ;
Newman, Aaron M. ;
Lorenz, Susanne ;
Smeland, Erlend B. ;
Alizadeh, Ash A. ;
Huse, Kanutte ;
Myklebust, June H. .
BLOOD ADVANCES, 2023, 7 (23) :7216-7230
[47]   In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma [J].
Knapp, Christopher M. ;
Whitehead, Kathryn A. .
EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (12) :1923-1937
[48]   Primary cutaneous large B-cell non-Hodgkin lymphoma in first-degree relatives [J].
Colovic, M. ;
Vidovic, A. ;
Colovic, N. ;
Perunicic-Jovanovic, M. ;
Tomin, D. .
BIOMEDICINE & PHARMACOTHERAPY, 2012, 66 (06) :425-427
[49]   Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma [J].
Veal, Gareth J. ;
Cole, Michael ;
Chinnaswamy, Girish ;
Sludden, Julieann ;
Jamieson, David ;
Errington, Julie ;
Malik, Ghada ;
Hill, Christopher R. ;
Chamberlain, Thomas ;
Boddy, Alan V. .
EUROPEAN JOURNAL OF CANCER, 2016, 55 :56-64
[50]   Evidence-based follow-up in patients with Hodgkin’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma [J].
Thomas Spanberger .
memo - Magazine of European Medical Oncology, 2020, 13 :55-59